Ki-67, a nuclear protein encoded by the MKI67 gene, serves as a crucial biomarker for cell proliferation and tumor aggressiveness. It is prominently expressed during active phases of the cell cycle and absent in quiescent cells. In breast cancer, Ki-67 plays a key role in tumor classification, aiding in the differentiation of subtypes like Luminal A and B, which helps guide prognosis and treatment decisions. Advanced technologies, including digital image analysis and miRNA profiling, are being developed to improve the accuracy and reliability of Ki-67, enhancing its application in personalized cancer therapies.
ABclonal's A20018 Ki67 Rabbit mAb was featured in a study conducted by Dr. Hu's Research Group at Huazhong University of Science and Technology. The study, titled "Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome-Lysosome Fusion in NSCLC," was published in Advanced Science on June 21, 2024. Ki-67 was utilized as a critical marker to evaluate tumor proliferation and therapeutic efficacy. Immunohistochemical analysis revealed a notable decrease in Ki-67 expression in tumor tissues after ALO treatment, demonstrating its effectiveness in inhibiting the proliferation of lung adenocarcinoma cells.
.png?width=1200&upscale=true&name=Cancer%20email%20header%20(1).png)
